Enliven Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Enliven Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($103.69M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($89.02M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($71.58M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($37.66M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($51.38M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($41.36M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($23.46M) | Mar 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($119.66M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($104.55M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($83.53M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($38.79M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($51.44M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($41.70M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($24.12M) | Mar 5, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $85.86M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $80.78M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $64.57M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $31.02M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $38.44M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $32.15M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $19.01M | Mar 5, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($70.30M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($73.19M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($61.27M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($32.08M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($46.77M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($37.40M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($21.88M) | Mar 5, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $476.17M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $325.76M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $271.87M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $83.30M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $93.65M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $90.84M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $33.30M | Mar 5, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.57M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $15.92M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $25.96M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $10.37M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $7.62M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $6.41M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.38M | Mar 5, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $459.60M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $309.85M | Mar 3, 2026 |
| FY2025 | Dec 31, 2023 | $245.91M | Mar 3, 2026 |
| FY2024 | Dec 31, 2022 | ($76.83M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | ($42.89M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $84.44M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | ($48.85M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | ($26.32M) | Mar 5, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($347.17M) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | ($243.47M) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | ($154.45M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($82.86M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($147.50M) | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | ($96.11M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($54.75M) | Mar 5, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.90M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | $124.12M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | $100.14M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $75.54M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $48.31M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $47.70M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $4.94M | Mar 5, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Feb 10, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | (12) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Feb 10, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.44M | Mar 3, 2026 |
| FY2025 | Dec 31, 2024 | 48.94M | Mar 3, 2026 |
| FY2024 | Dec 31, 2023 | 41.29M | Mar 13, 2025 |
| FY2024 | Feb 23, 2023 | 41.01M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 3.57M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 26.29M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | 17.55M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 702,510 | Mar 5, 2021 |